BLDR
Builders FirstSource, Inc.
BLDR trails on the overall score without a compensating advantage in the available component scores.
CAT
Caterpillar Inc.
CAT has the edge over BLDR overall, supported by stronger modeled upside and lower modeled downside.
BLDR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
BLDR's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
BLDR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $2.82 | -95% |
| Fair | 14x | $5.19 | -91% |
| Expensive | 21x | $7.90 | -87% |
| Forward | 23x | $60.12 | — |
| Current | 158x | $60.12 | — |
Historical ranges are pointers, not guarantees.
BLDR's PE is in its expensive range at 158x. On analysts' estimates for next year's earnings, today's price would be 23x.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT has the edge over BLDR in the historical PE scenario, which offers more potential upside but is not a forecast.
BLDR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong decline | |
| Stable | |
| Weakening | |
| Moderate | |
| Low |
Analysts expect BLDR's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
CAT has the edge over BLDR on the outlook, with more favorable earnings and revenue expectations.
BLDR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.62 | +590% |
| Q3 2026 | $0.38 | -93% |
| Q2 2026 | $0.92 | -86% |
| Q1 2026 | $2.62 | -66% |
| Q4 2025 | $3.89 | -57% |
| Q3 2025 | $5.25 | -48% |
| Q2 2025 | $6.59 | -42% |
| Q1 2025 | $7.80 | -33% |
| Q4 2024 | $9.06 | -24% |
BLDR's earnings per share have fallen from their peak: $0.38 over the past year, against $16.82 in late 2022.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over BLDR on earnings, with more consistent year-over-year improvement.
BLDR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.9B | -2.2% |
| Q2 2026 | $3.9B | -8.8% |
| Q1 2026 | $3.3B | -10% |
| Q4 2025 | $3.4B | -12% |
| Q3 2025 | $3.9B | -6.9% |
| Q2 2025 | $4.2B | -5% |
| Q1 2025 | $3.7B | -6% |
| Q4 2024 | $3.8B | -8% |
BLDR's revenue has slid since its 2022 peak: $3.9B last quarter, down 2.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 3.3% | -4 points |
| Q1 2026 | 0.5% | -4.5 points |
| Q4 2025 | 1.8% | -6.1 points |
| Q3 2025 | 5.8% | -4.3 points |
| Q2 2025 | 7.3% | -3.6 points |
| Q1 2025 | 5% | -4.6 points |
| Q4 2024 | 8% | -3.9 points |
BLDR's operating margin was 2.6% last quarter, down 3.2 points from the same quarter a year ago, near the bottom of its range since 2019.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over BLDR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over BLDR on profitability, with a higher operating margin.
BLDR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $73.9M | -84% |
| Q2 2026 | $30M | -88% |
| Q1 2026 | $40.7M | +26% |
| Q4 2025 | $106.7M | -61% |
| Q3 2025 | $461.9M | -27% |
| Q2 2025 | $252.3M | -31% |
| Q1 2025 | $32.4M | -86% |
| Q4 2024 | $273.8M | -47% |
BLDR still generates free cash flow, though less than at its 2022 peak: $251M over the past year.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the edge over BLDR on cash flow, with more consistent year-over-year improvement.
BLDR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +71K shares |
| 1 year | -3% | -3.3M shares |
| 3 years | -14% | -18.2M shares |
| 5 years | -48% | -98M shares |
| Available history | -8% | -9.4M shares |
BLDR has the edge over CAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $3.5M |
| Q1 2026 | $300.1M |
| Q4 2025 | — |
| Q3 2025 | $1,000 |
| Q2 2025 | $401.6M |
| Q1 2025 | $12.3M |
| Q4 2024 | $363.8M |
BLDR spent $304M buying back its own shares over the past year, down 61% from the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has 461M diluted shares, down 2.1% from a year ago, with $8.1B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
BLDR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.1x | High |
| Q2 2026 | 4.4x | High |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.1x | Elevated |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 1.7x | Healthy |
BLDR's net debt is about 5.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over BLDR on leverage, with a lower net debt burden relative to earnings.
BLDR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 48.0 | Neutral |
BLDR's weekly RSI is 41 (neutral) and its Stochastic is 48 (neutral).
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
BLDR PE vs Industrials Sector
| Metric | BLDR | Sector median | Relative |
|---|---|---|---|
| PE | 158x | 24x | 557% above |
| PE % | 99 | 58 | 41 pts above |
BLDR is trading at 158x earnings, a 557% premium to the Industrials sector's median of 24x.
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT has the edge over BLDR on valuation relative to its sector.
BLDR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.4 | 2.9% above |
| 20 week MA | $65.5 | 8.3% below |
| 50 week MA | $83.3 | 28% below |
| 100 week MA | $106.2 | 43% below |
| 200 week MA | $126.5 | 52% below |
BLDR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has the edge over BLDR on trend strength, trading above more of its moving averages.
BLDR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $42.3 | +66% |
| 2021 | $42.3 | $82.2 | +94% |
| 2022 | $82.2 | $65.3 | -21% |
| 2023 | $65.3 | $166.9 | +156% |
| 2024 | $166.9 | $145.1 | -13% |
| 2025 | $145.1 | $104.0 | -28% |
| 2026 YTD | $104.0 | $60.1 | -42% |
BLDR has finished lower in three of the last six years. It's down 42% so far in 2026.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over BLDR on returns for 2026, with the stronger performance.